The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study

Table 4 Univariate analysis for pRR and biomarkers^#

Biomarker	DEC n = 58		EFC n = 37		VFC n = 23
	pRR (%)	p**	pRR (%)	p**	pRR (%)	p**
ER
negative	67.9	0.000**	50.0	0.003**	57.1	0.040**
positive	20.0		3.7		11.1
PR
negative	58.1	0.014**	26.3	0.180	58.3	0.089
positive	25.9		5.6		18.2
HER2
negative	16.7	0.001**	25.0	0.371	55.6	0.383
positive	61.8		16.2		28.6
P-gp
negative	38.6	0.223	13.3	0.315	42.1	1.000
positive	57.1		28.6		25.0
MRP
negative	32.0	0.137	7.7	0.394	22.2	0.228
positive	51.5		20.8		50.0
GST-pi
negative	42.9	0.963	8.7	0.173	30.8	0.417
positive	43.5		28.6		50.0
Topo-II
negative	26.1	0.034**	6.7	0.368	42.9	1.000
positive	54.3		22.7		37.5

^# pRR: pathologic response rate
* D docetaxel, E epirubicin, C cyclophosphamide, F 5-Fluorouracil, V vinorelbine or vincristine
**p < 0.05 is considered statistically significant

ISSN: 1471-2407